Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL); ODM derived from:


Versions (1) ▾
  1. 7/31/17
Uploaded on:

July 31, 2017

No DOI assigned. To request one pleaselog in.
Creative Commons BY-NC 3.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Philadelphia Positive Acute Lymphoblastic Leukemia NCT00199186

Eligibility Philadelphia Positive Acute Lymphoblastic Leukemia NCT00199186

Inclusion Criteria
male or female patients
age > 55 years (biological age)
diagnosis of ph1 chromosome-positive all (pre-b, common- or pre-pre-b all)
newly diagnosed, lymphoid blast crisis of chronic myeloid leukemia
only pre-phase chemotherapy prior to study start
world health organization (who) status 0, 1 or 2
voluntary written informed consent
Exclusion Criteria
creatinine levels more than 2 x the upper limit of normal (uln)
total serum bilirubin more than 1.5 x the uln
ast (sgot) or alt (sgpt) more than 5 x the uln
any other prior antineoplastic treatment except for pre-phase chemotherapy
active central nervous system (cns) leukemia
new york heart association (nyha) grade 3/4 cardiac disease
active severe infection
serious concomitant medical condition
patients with a history of non-compliance to medical regimens